| Code | CSB-RA001370MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Adrecizumab, targeting adrenomedullin (ADM), a multifunctional peptide hormone involved in cardiovascular homeostasis and vascular regulation. ADM plays critical roles in vasodilation, endothelial barrier function, and fluid balance through its interaction with calcitonin receptor-like receptor (CALCRL) and receptor activity-modifying proteins. Dysregulation of ADM signaling is implicated in sepsis, septic shock, acute respiratory distress syndrome, and various cardiovascular disorders, where elevated ADM levels correlate with disease severity and adverse outcomes.
Adrecizumab, the reference antibody, is a non-neutralizing humanized monoclonal antibody designed to bind the mid-regional portion of ADM, effectively stabilizing circulating ADM levels and modulating its bioavailability during pathological conditions. This biosimilar provides researchers with a valuable tool for investigating ADM-mediated pathways in inflammatory responses, vascular permeability, and hemodynamic regulation. It supports studies exploring therapeutic interventions for conditions characterized by ADM imbalance, including critical care medicine research and cardiovascular disease models.
There are currently no reviews for this product.